Brief: Everest Medicines Announces Partner Providence Reports Positive Top-Line Data From Phase 2 Primary Immunization Trial For Mrna Covid-19 Vaccine Candidate In Adults

Everest Medicines

19/10/2022 13:17

Oct 19 (Reuters) - Everest Medicines Ltd  1952.HK :
    * EVEREST MEDICINES ANNOUNCES PARTNER PROVIDENCE REPORTS
POSITIVE
TOP-LINE DATA FROM PHASE 2 PRIMARY IMMUNIZATION TRIAL FOR MRNA
COVID-19 VACCINE CANDIDATE IN ADULTS
    * EVEREST MEDICINES LTD- PTX-COVID19-B WAS WELL TOLERATED
WITH NO
SAFETY SIGNALS
    * EVEREST MEDICINES LTD- EVEREST IS FILING IND APPLICATIONS
FOR
PHASE 3 CLINICAL TRIALS FOR BOOSTER INDICATION
    * EVEREST MEDICINES LTD - LEVELS OF NEUTRALIZING ANTIBODIES
GENERATED BY PTX-COVID19-B WERE NON-INFERIOR TO COMIRNATY
    * EVEREST MEDICINES LTD- NO UNSOLICITED TREATMENT-RELATED
SERIOUS
ADVERSE EVENTS WERE REPORTED IN EITHER GROUP
    * EVEREST - PLANS TO FILE INDS FOR OMICRON-CONTAINING
BIVALENT
BOOSTER CANDIDATE, EVER-COVID19-M1.2, IN H2 OF 2022 IN CHINA,
OTHER EVEREST TERRITORIES

Source text for Eikon:  ID:nPnJrTKTa 
Further company coverage:  1952.HK 
 ((Reuters.Briefs@thomsonreuters.com;))